Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life - Episode 7

Adverse Events Seen With JAK Inhibitors for Myelofibrosis

January 5, 2024
Christine Cooper, RN, BSN

,
Aaron Gerds, MD, MS

The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.